Enanta Pharmaceuticals Inc (ENTA) — 10-K Filings
All 10-K filings from Enanta Pharmaceuticals Inc. Browse 2 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (2)
-
Enanta Shifts Royalty Focus, Eyes RSV & Immunology Growth Amid Losses
— Nov 19, 2025 Risk: high
Enanta Pharmaceuticals, Inc. (ENTA) reported a significant strategic shift in its revenue stream, with 54.5% of its reported revenues from MAVYRET/MAVIRET royal -
Enanta Pharmaceuticals Files 2024 Annual Report
— Nov 27, 2024 Risk: low
Enanta Pharmaceuticals, Inc. filed its annual report for the fiscal year ended September 30, 2024. The company is incorporated in Delaware and headquartered in
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX